Buy Now
$4,123 $4,850
15% off
$4,840 $6,050
20% off
$5,845 $8,350
30% off
Buy now
Premium Report Details
Base Year: 2024
Companies covered: 12
Tables & Figures: 124
Countries covered: 19
Pages: 135
Download Free PDF

Prurigo Nodularis Treatment Market
Get a free sample of this reportGet a free sample of this report Prurigo Nodularis Treatment Market
Is your requirement urgent? Please give us your business email for a speedy delivery!
Prurigo Nodularis Treatment Market Size
The global prurigo nodularis treatment market was valued at USD 2.1 billion in 2024. The market is expected to grow from USD 2.2 billion in 2025 to USD 3.1 billion in 2034, at a CAGR of 4.1% during the forecast period. The market is steadily gaining momentum, fueled by a combination of growing incidence of the disease, increased awareness of available treatments, and notable advancements in biologic drug development.
For example, the National Organization of Rare Disorders (NORD) reports that PN affects roughly 72 individuals per 100,000 annually in the U.S., equating to approximately 87,634 new adult cases each year among those aged 18 to 64. This growing disease burden, particularly among individuals with pre-existing dermatological conditions such as atopic dermatitis, is intensifying the demand for effective therapeutic interventions.
PN significantly affects adults with age 20 to 60 and is generally linked to systemic health issues, including hepatic and renal dysfunction, neurological disorders, and chronic inflammatory skin diseases like eczema and bullous pemphigoid. The increasing diagnosis rate, heightened awareness among both healthcare professionals and patients, and the severely debilitating nature of PN are other factors propelling market expansion. In response to this escalating need, global research and development efforts have gained momentum. Pharmaceutical companies are making substantial investments in innovative therapies designed to disrupt the itch–scratch cycle and address the underlying inflammatory mechanisms of PN.
For instance, in November 2020, the U.S. FDA granted breakthrough therapy designation to Vixarelimab, a monoclonal antibody that targets the oncostatin M receptor beta (OSMRβ), for the treatment of pruritus associated with PN. These regulatory designations not only facilitate in reducing the duration of approval but also demonstrate the promising therapeutic potential of emerging drugs, thereby boosting confidence among clinicians and investors.
In addition, increased funding from government agencies and private investors, along with strategic efforts by leading pharmaceutical companies to develop targeted biologics, is opening up new opportunities for market expansion. The introduction of approved biologics such as Dupilumab and recent regulatory clearances for therapies like Nemolizumab are reinforcing the treatment landscape. These advanced therapies offer more effective solutions compared to conventional treatments like corticosteroids and antihistamines, thereby accelerating market expansion.
Prurigo nodularis treatment encompasses a variety of therapeutic products aimed at managing and alleviating the symptoms of this chronic, intense skin disorder, which is characterized by firm, nodular lesions and persistent inflammation. These include majorly corticosteroids, antihistamines, biologics, emollients, and capsaicin cream, among others.
Prurigo Nodularis Treatment Market Trends
Prurigo Nodularis Treatment Market Analysis
In 2021, the global market was valued at USD 2.04 billion and experienced growth to reach USD 2.07 billion in 2022 and USD 2.1 billion in 2023.
Based on the product type, the global market is segmented into corticosteroids, antihistamines, emollients, capsaicin cream, biologics, calcineurin inhibitors, immunosuppressants, and other product types. The corticosteroids segment dominated the market and was valued at USD 650.4 million in 2024.
Based on the route of administration, the global prurigo nodularis treatment market is classified into topical, oral, and parenteral. The topical segment held the highest market share of 55.3% in 2024.
Based on the medication type, the global prurigo nodularis treatment market is categorized into prescription and OTC. The prescription segment is expected to grow at a significant CAGR of 3.8% during the forecast timeframe.
Based on the distribution channel, the global prurigo nodularis treatment market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated in 2024 and is anticipated to reach USD 1.6 billion by 2034.
The North America prurigo nodularis treatment market dominated the global market with a market share of 41.3% in 2024.
The U.S. market was valued at USD 783.5 million and USD 792.3 million in 2021 and 2022, respectively. The market size reached USD 816.6 million in 2024, growing from USD 803.6 million in 2023.
Europe prurigo nodularis treatment market accounted for USD 609.4 million in 2024 and is anticipated to show lucrative growth over the forecast period.
Germany prurigo nodularis treatment market is anticipated to witness considerable growth over the analysis period.
The Asia Pacific prurigo nodularis treatment market is anticipated to grow at the highest CAGR of 4.4% during the analysis timeframe.
China prurigo nodularis treatment market is predicted to grow significantly over the forecast period.
Brazil is expected to experience significant growth in the Latin America prurigo nodularis treatment market over the coming years.
Saudi Arabia prurigo nodularis treatment market is poised to witness substantial growth in Middle East and Africa market during the forecast period.
Prurigo Nodularis Treatment Market Share
The global market is currently in a phase of evolution, with the competitive landscape shaped by a combination of established pharmaceutical giants and emerging specialty biotech firms. Historically, the market was dominated by topical corticosteroids, antihistamines, and emollients, but with the recent approval of targeted biologics such as Dupixent (Sanofi) and Nemluvio (Galderma), the focus is rapidly shifting toward systemic therapies with disease-modifying potential. As a result, the competitive dynamics are being redefined, particularly in regions like the U.S. and Europe where regulatory support and commercial access are strong.
The top 5 players including Sanofi, Galderma, Pfizer, GlaxoSmithKline, and Johnson & Johnson account for approximately 55% – 65% of the global market share. As clinical trials advance and new biologics or neuromodulators gain approval, market share is expected to redistribute, favoring companies with targeted and differentiated offerings for this highly underserved and complex condition.
Prurigo Nodularis Treatment Market Companies
Few of the prominent players operating in the prurigo nodularis treatment industry include:
Prurigo Nodularis Treatment Industry News
The prurigo nodularis treatment market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:
Market, By Product Type
Market, By Route of Administration
Market, By Medication Type
Market, By Distribution Channel
The above information is provided for the following regions and countries: